Resmetirom
Madrigal Pharmaceuticals · MGL-3196 · VIA-3196
FollowEvery change as it happens, and a Monday email
Trials
7 active
14 in total · 2 in the EU
What this is
- How it works
- Thyroid hormone receptor beta (THR-β) agonist
- How it’s given
- “All study medications will be administered according to their labels: • REZDIFFRA- Label weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily”In the company’s words, NCT07848191 on ClinicalTrials.gov
- Tested for
- MASH - Metabolic Dysfunction-Associated Steatohepatitis (4 trials), NASH, Cirrhosis, Liver, Non-Alcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis, MASH, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Main trialPhase 4
- “To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)”In the company’s words, NCT07848191 on ClinicalTrials.gov
- Other names
- MGL-3196 · VIA-3196 · Rezdiffra
- Given with
- Actos (Takeda Pharms USA), Farxiga (Astrazeneca AB)Other companies’ drugs in its trials
Other drugs for MASH - Metabolic Dysfunction-Associated Steatohepatitis
- ElafibranorIpsen · Phase 3
- MosliciguatPulmovant, Inc. · Phase 3
- SC1011JOYO Pharma · Phase 2/3
- Saroglitazar MagnesiumZydus Therapeutics Inc. · Phase 3
- NerandomilastBoehringer Ingelheim · Phase 3
- EHSG-KFCUTISS AG · Phase 3
Coming up7
- DecPhase 3 trial completes · ClinicalTrials.gov
- Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Nov 2027Phase 4 trial completes · ClinicalTrials.gov
- Nov 2027Phase 1 trial completes · ClinicalTrials.gov
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- Aug 2028Phase 2 trial completes · ClinicalTrials.gov
- Jul 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
FDA approvals1
- 14 Mar 2024REZDIFFRA MADRIGAL · Application NDA217785
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Nov 2027 | Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis | |
| Phase 3Active, not recruiting | Dec 2026 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | |
| Phase 3Active, not recruiting | Mar 2027 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | |
| Phase 3Active, not recruiting | Jan 2028 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | |
| Phase 2Recruiting | Aug 2028 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | |
| Phase 2Recruiting | Jul 2029 | Study of Resmetirom in Children and Adolescents With MASH | |
| Phase 1Recruiting | Nov 2027 | Resmetirom in Patients With MASH and HFpEF | |
| Phase 3Completed | 6 Jan 2023 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients | |
| Phase 2Completed | 25 Oct 2017 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | |
| Phase 2Completed | 15 Jan 2018 | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) | |
| Phase 1Completed | Oct 2011 | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects | |
| Phase 1Completed | Oct 2015 | Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin | |
| Phase 1Completed | 4 Aug 2021 | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects | |
| Phase 1Completed | 16 Sep 2024 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026